Effect of hypomethylating agents in the treatment of intermediate-and high-risk myelodysplasia syndrome

YAN Zonghai; WU Yanming; DING Gang; LI Chengjun; SUN Guangyu

doi:10.7619/jcmp.20233639

Journal of Clinical Medicine in Practice > 2024 > 28(5): 75-78, 84. > DOI: 10.7619/jcmp.20233639

YAN Zonghai, WU Yanming, DING Gang, LI Chengjun, SUN Guangyu. Effect of hypomethylating agents in the treatment of intermediate-and high-risk myelodysplasia syndrome[J]. Journal of Clinical Medicine in Practice, 2024, 28(5): 75-78, 84. DOI: 10.7619/jcmp.20233639

Citation:

PDF (906 KB)

Effect of hypomethylating agents in the treatment of intermediate-and high-risk myelodysplasia syndrome

Department of Hematology, Chaohu Hospital Affiliated to Anhui Medical University, Chaohu, Anhui, 238000

More Information

Received Date: November 13, 2023
Revised Date: January 01, 2024
Available Online: March 21, 2024

Graphical Abstract

Abstract

Abstract

Objective
To observe the clinical effect of hypomethylating agents (HMAs) in the treatment of patients with intermediate- and high-risk myelodysplastic syndrome (MDS).
Methods
A retrospective study was conducted in 58 patients with intermediate-and high-risk MDS. The study group(25 patients) received azacitidine or decitabine for hypomethylating treatment, while the control group(33 patients) received routine symptomatic supportive treatment. The clinical efficacy, hematologic parameters, quality of life, and adverse events were observed and compared between the two groups.
Results
After treatment, the complete remission rate, objective response rate, and disease control rate were higher in the study group than in the control group, while the disease progression rate was lower (P < 0.05). The 1-year survival rate was 92.00% in the study group, which was higher than 75.76% in the control group, but the difference showed no statistically significant (P>0.05). After treatment, hemoglobin, white blood cell, and platelet levels were higher in both groups than before treatment, and were higher in the study group than in the control group (P < 0.05). The total incidence of adverse events was lower in the study group than that in the control group (P < 0.05). After treatment, the quality of life scores (physical function, cognitive function, emotional function, role function, and social function) were higher in the study group than those in the control group (P < 0.05).
Conclusion
HMAs treatment is superior to routine symptomatic supportive treatment in patients with intermediate-and high-risk MDS, and not only improves the quality of life but also has good safety.
- hypomethylating agents,
- myelodysplastic syndrome,
- intermediate-and high-risk,
- azacitidine,
- decitabine,
- quality of life

FullText(HTML)

References (25)

References

[1]	PATNAIK M M, TEFFERI A. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) -"2021 update on diagnosis, risk-stratification, and management"[J]. Am J Hematol, 2021, 96(3): 379-394. doi: 10.1002/ajh.26090
[2]	梅琛, 佟红艳. 去甲基化药物治疗骨髓增生异常综合征的临床现状与前景[J]. 国际输血及血液学杂志, 2021, 44(4): 284-293. doi: 10.3760/cma.j.cn511693-20200327-0007
[3]	佟红艳. 骨髓增生异常综合征去甲基化治疗: 地西他滨还是阿扎胞苷?[J]. 临床血液学杂志, 2019, 32(11): 841-846, 850. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ201911006.htm
[4]	吴雪, 陈宝安. 2014 NCCN指南骨髓增生异常综合征新进展[J]. 白血病·淋巴瘤, 2014, 23(9): 515-517. doi: 10.3760/cma.j.issn.1009-9921.2014.09.002
[5]	万崇华, 陈明清, 张灿珍, 等. 癌症患者生命质量测定量表EORTC QLQ-C30中文版评介[J]. 实用肿瘤杂志, 2005, 20(4): 353-355. doi: 10.3969/j.issn.1001-1692.2005.04.028
[6]	王佩, 董照, 原现华, 等. 阿扎胞苷对中高危骨髓增生异常综合征的临床疗效观察: 评《骨髓增生异常综合征肖志坚2018观点》[J]. 中国临床药理学与治疗学, 2021, 26(7): 841-841. https://www.cnki.com.cn/Article/CJFDTOTAL-YLZL202107021.htm
[7]	CEDENA M T, RAPADO I, SANTOS-LOZANO A, et al. Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes[J]. Oncotarget, 2017, 8(63): 106948-106961. doi: 10.18632/oncotarget.22157
[8]	LIN M E, HOU H A, TSAI C H, et al. Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome[J]. Clin Epigenetics, 2018, 10: 42. doi: 10.1186/s13148-018-0476-1
[9]	陈园园, 石锐, 郭素青, 等. 地西他滨治疗伴DNA甲基转移酶基因突变的骨髓增生异常综合征患者的疗效分析[J]. 中国实验血液学杂志, 2020, 28(4): 1292-1297. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY202004040.htm
[10]	BAO Z H, ZHAO H G, YU H E. Clinical efficacy and prognostic factors of decitabine for treatment of myelodysplastic syndrome[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2018, 26(6): 1702-1707.
[11]	FANG K, QI J Q, ZHOU M, et al. Clinical characteristics, prognosis, and treatment strategies of TP53 mutations in myelodysplastic syndromes[J]. Clin Lymphoma Myeloma Leuk, 2022, 22(4): 224-235. doi: 10.1016/j.clml.2021.09.013
[12]	童春, 叶芳, 李宁宁, 等. 不同剂量地西他滨治疗高危骨髓增生异常综合征患者疗效及安全性的回顾性分析[J]. 中国实验血液学杂志, 2021, 29(6): 1845-1850. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY202106028.htm
[13]	王欢, 郝建萍. 阿扎胞苷治疗对骨髓增生异常综合征患者近期疗效及生存率的影响[J]. 医学食疗与健康, 2022, 20(11): 4-6, 85. https://www.cnki.com.cn/Article/CJFDTOTAL-YXSL202211002.htm
[14]	鲍振华, 赵洪国, 于虹娥. 地西他滨治疗骨髓增生异常综合征的临床观察及预后因素分析[J]. 中国实验血液学杂志, 2018, 26(6): 1702-1707. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201806023.htm
[15]	常炳庆, 孙婉玲. 去甲基化药物在骨髓增生异常综合征治疗中的进展[J]. 中国药物警戒, 2018, 15(9): 560-563. doi: 10.3969/j.issn.1672-8629.2018.09.012
[16]	GARCIA-MANERO G, GRIFFITHS E A, STEENSMA D P, et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study[J]. Blood, 2020, 136(6): 674-683. doi: 10.1182/blood.2019004143
[17]	FENAUX P, SANTINI V, SPIRITI M A A, et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS[J]. Leukemia, 2018, 32(12): 2648-2658. doi: 10.1038/s41375-018-0118-9
[18]	STAHL M, DEVEAUX M, WITTE T D, et al. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort[J]. Blood Adv, 2018, 2(14): 1765-1772. doi: 10.1182/bloodadvances.2018019414
[19]	MOSSNER M, JANN J C, NOWAK D, et al. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the German MDS study group (GMDS)[J]. Leukemia, 2016, 30(9): 1956-1959. doi: 10.1038/leu.2016.111
[20]	ZHOU L, MCMAHON C, BHAGAT T, et al. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase[J]. Cancer Res, 2011, 71(3): 955-963. doi: 10.1158/0008-5472.CAN-10-2933
[21]	WEI Y, DIMICOLI S, BUESO-RAMOS C, et al. Toll-like receptor alterations in myelodysplastic syndrome[J]. Leukemia, 2013, 27(9): 1832-1840. doi: 10.1038/leu.2013.180
[22]	CARNEIRO B A, EL-DEIRY W S. Targeting apoptosis in cancer therapy[J]. Nat Rev Clin Oncol, 2020, 17(7): 395-417. doi: 10.1038/s41571-020-0341-y
[23]	NAKADA D. Venetolax with azacitidine drains fuel from AML stem cells[J]. Cell Stem Cell, 2019, 24(1): 7-8. doi: 10.1016/j.stem.2018.12.005
[24]	BEWERSDORF J P, ZEIDAN A M. Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes[J]. Leukemia, 2019, 33(6): 1303-1312. doi: 10.1038/s41375-019-0448-2
[25]	李瑞萍, 马艳萍. 罗特西普治疗骨髓增生异常综合征的研究进展[J]. 中国肿瘤临床, 2023, 50(18): 964-968. doi: 10.12354/j.issn.1000-8179.2023.20230874

[1]	WANG Jinxia, WANG Juxin, LIU Jing, GENG Chang. Effect of Yiqi Tongluo Anshen Recipe combined with statins on coronary blood flow and blood pressure in patients with coronary heart disease and hypertension[J]. Journal of Clinical Medicine in Practice, 2023, 27(23): 43-46, 53. DOI: 10.7619/jcmp.20233055
[2]	LIU Yongtao, SU Yueming. Effect of Rosuvastatin Calcium Tablets in the treatment of patients with coronary heart disease and heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(10): 60-63. DOI: 10.7619/jcmp.202010015
[3]	ZHANG Hui, GU Jing. Efficiency analysis of bisoprolol combined with amlodipine in treating elderly patients with coronary heart disease complicated with hypertension[J]. Journal of Clinical Medicine in Practice, 2019, (2): 29-32. DOI: 10.7619/jcmp.201902009
[4]	FAN Jun. Application of continuous nursing intervention for elderly coronary heart disease patients complicated with chronic hypertension[J]. Journal of Clinical Medicine in Practice, 2018, (4): 9-12. DOI: 10.7619/jcmp.201804003
[5]	JU Yanling, ZANG Xuelian, ZHAO Xu. Effect of amlodipine atorvastatin calcium tablet on IMT, PV, TNF, CRP, and blood lipid level of coronary heart disease and high blood pressure patients complicated with carotid atherosclerosis[J]. Journal of Clinical Medicine in Practice, 2017, (1): 14-18. DOI: 10.7619/jcmp.201701004
[6]	DONG Feng, YANG Chengjian, YE Xinhe, WANG Renrong, CHEN Hao. Efficacy of nifedipine sustained-release tablets combined with enalapril on treatment of coronary heart disease patients complicated with hypertension and their influence on NO, CRP and HCY[J]. Journal of Clinical Medicine in Practice, 2016, (21): 10-13. DOI: 10.7619/jcmp.201621004
[7]	LIN Fang. Effect of time nursing on disease controlling of hypertension patients combined with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2016, (14): 144-146. DOI: 10.7619/jcmp.201614045
[8]	TANG Bo. Clinical effect of rosuvastatin versus atorvastatin in treatment of coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2015, (Z1): 168-169.
[9]	LI Xiaoli, LI Fei. Efficacy of atorvastatin and amlodipine besylate for coronary heart disease complicated by cerebral infarction and its effect on blood lipids[J]. Journal of Clinical Medicine in Practice, 2015, (15): 8-10. DOI: 10.7619/jcmp.201515003
[10]	DU Jinying, LIU Dayong, ZHANG Haiying. Clinical significance of ST-T changes in electrocardiogram to diagnose coronary heart disease in hypertensive patients[J]. Journal of Clinical Medicine in Practice, 2014, (5): 106-107,110. DOI: 10.7619/jcmp.201405036

Cited By

Cited by

Periodical cited type(20)

1.	邬伟莉. 氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的护理研究. 临床合理用药杂志. 2020(25): 44-45 .
2.	陈小敏，吴建华，阴慧华. 老年冠心病合并高血压患者实施急诊优质护理的价值体会. 心血管病防治知识. 2020(22): 56-58 .
3.	陈红. 健康管理对氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的影响. 智慧健康. 2020(33): 185-187 .
4.	骆军武，凌涛，叶志辉，孙大勇. 氨氯地平阿托伐他汀治疗高血压冠心病的效果. 中国卫生标准管理. 2019(08): 58-60 .
5.	任桂花. 对氨氯地平阿托伐他汀钙片治疗高血压冠心病的患者实施护理干预的临床疗效观察. 世界最新医学信息文摘. 2019(49): 294+305 .
6.	仇中叶，曹树红. 健康教育对冠心病合并高血压患者生活质量的影响分析. 基层医学论坛. 2019(27): 3962-3964 .
7.	曾林飞，伍香姑. 血脂康胶囊、氨氯地平联合阿托伐他汀钙片治疗高血压病合并冠心病的临床效果. 实用中西医结合临床. 2019(12): 6-8 .
8.	饶建云，张瑞，范婷. 预见性护理在冠心病介入治疗患者中的应用效果评价. 护理实践与研究. 2018(13): 40-42 .
9.	阚铮. 探讨氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床疗效. 世界最新医学信息文摘. 2018(07): 103 .
10.	孙晓云. 氨氯地平联合阿托伐他汀钙片治疗高血压合并冠心病的临床效果. 临床医学研究与实践. 2018(17): 32-33 .
11.	赵虹. 氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床疗效探讨. 中国处方药. 2018(03): 80 .
12.	李颖. 护理干预应用于氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的疗效观察. 中国实用医药. 2018(09): 168-169 .
13.	韩花. 探析在氨氯地平阿托伐他汀钙片治疗高血压冠心病中实施护理干预的效果. 世界最新医学信息文摘. 2018(79): 125+131 .
14.	李万锋. 氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床疗效研究. 中国实用医药. 2018(27): 120-121 .
15.	岑运光，李伟，张旭日，吴多智. 银杏叶注射液对老年高血压冠心病患者内皮素及冠脉血流的影响. 中华中医药学刊. 2018(11): 2754-2756 .
16.	刘春晖. 阿托伐他汀对冠心病患者的效果及其临床护理探讨. 药品评价. 2018(24): 43-46 .
17.	张卫全. 氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的效果分析. 中国全科医学. 2018(S2): 145-147 .
18.	印云. 对高血压合并冠心病患者实施综合护理的效果观察. 当代医药论丛. 2017(24): 260-261 .
19.	杨妮. 护理干预应用于冠心病护理的效果分析. 现代医学与健康研究电子杂志. 2017(04): 137 .
20.	韦桂丹. 氨氯地平阿托伐他汀在高血压合并冠心病患者中的应用价值. 家庭医药.就医选药. 2018(01): 174-175 .

Other cited types(0)

Get Citation

PDF

XML

Article views (126) PDF downloads (5) Cited by(20)

Turn off MathJax

Article Contents

Abstract

References

Effect of hypomethylating agents in the treatment of intermediate-and high-risk myelodysplasia syndrome

Abstract

References

Related Articles

Cited by

Periodical cited type(20)

Other cited types(0)

Catalog

Effect of hypomethylating agents in the treatment of intermediate-and high-risk myelodysplasia syndrome

Abstract

References

Related Articles

Cited by

Periodical cited type(20)

Other cited types(0)

Catalog

Export File

Citation

Format

Content